Radiopharmaceutical Theranostics Market Overview  

The radiopharmaceutical theranostics market is gaining steady clinical and commercial traction as oncology care increasingly favors targeted, image-guided treatment pathways. According to Mordor Intelligence, the radiopharmaceutical theranostics market size is projected to grow from USD 2.40 billion in 2025 to USD 2.66 billion in 2026, and further expand to USD 4.46 billion by 2031. This growth reflects rising confidence in radioligand therapies that combine precise diagnostics with tumor-directed radiation treatment. 

Theranostics integrates diagnostic imaging and therapy using the same molecular target, allowing clinicians to identify disease, deliver treatment, and monitor response within a single clinical framework. Hospitals and cancer centers are increasingly adopting this approach due to its predictable outcomes, reduced trial-and-error in therapy selection, and improved workflow efficiency.. 

Radiopharmaceutical Theranostics Market Trends Shaping Industry Demand 

Growing Use of Lutetium-Based Therapies 

Lutetium-based treatments for prostate and neuroendocrine cancers are gaining wider hospital acceptance as combined imaging and therapy improves treatment confidence and repeat care cycles. 

Rising Focus on Alpha-Emitting Isotopes 

Alpha-emitting radiopharmaceuticals are drawing attention for advanced and resistant cancers, with improving production support expanding their role beyond early clinical adoption. 

Improved Operational Efficiency in Radiopharmacies 

Automation, standardized dosing, and digital planning tools are helping providers manage short isotope lifecycles and compliance, supporting steady radiopharmaceutical theranostics market growth. 

Radiopharmaceutical Theranostics Market Segmentation  

By Isotope 

By Cancer Type 

By Application 

By End User 

By Geography 

Radiopharmaceutical Theranostics Industry Leaders 

The competitive environment within the radiopharmaceutical theranostics industry is defined by supply reliability, regulatory expertise, and clinical depth. Market participants are strengthening control over isotope production, formulation, and distribution to reduce operational risk and ensure treatment continuity. 

Key players include: 

Radiopharmaceutical Theranostics Market Conclusion 

The outlook for the radiopharmaceutical theranostics market forecast remains favorable as oncology care continues to shift toward precision-based treatment models. Integrated diagnostic-therapeutic workflows are delivering measurable value for clinicians, patients, and health systems, reinforcing long-term adoption. 

While challenges related to isotope logistics, workforce training, and regulatory coordination persist, ongoing infrastructure investments are steadily reducing these barriers. Hospitals are expanding internal capabilities, and radiopharmacies are improving last-mile delivery efficiency, supporting broader geographic reach. 

Overall, the radiopharmaceutical theranostics market growth trajectory reflects a balanced expansion across diagnostics and therapy, supported by validated clinical outcomes and scalable care models. As the industry continues to align imaging with treatment decision-making, the radiopharmaceutical theranostics market is positioned as a durable component of modern cancer management.